Black Diamond Therapeutics, Inc.
139 Main Street, Suite 301
Cambridge
MA
02142
United States
Website: http://www.blackdiamondtherapeutics.com/
Email: info@bdtherapeutics.com
About Black Diamond Therapeutics, Inc.
Our Vision
Precision Cancer Medicines for Every Genetically-Defined Patient
Company Overview
Black Diamond Therapeutics: A Next-Wave Cancer Precision Medicine Company
Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies.
Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
27 articles with Black Diamond Therapeutics, Inc.
-
Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board
9/29/2020
- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Robert A. Ingram as the Chairman of its Board of Directors. Brad Bolzon, Ph.D., Chairman and Managing Director at Versant Ventures and Black Diamond’s founding Chairman, will remain on the Company’s board. “As we welcome B
-
BioSpace Movers & Shakers, Sept. 11
9/11/2020
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers. -
Black Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference
9/10/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the Morgan Stanley 18 th Annual Global Healthcare Conference. The presentation will take place on Tuesday, Septemb
-
Black Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer
9/8/2020
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the appointment of Rachel Humphrey, M.D., as Chief Medical Officer.
-
Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/11/2020
• Obtained U.S. FDA Fast Track designation for BDTX-189 for the treatment of adult patients with a solid tumor harboring an allosteric HER2 mutation or an EGFR or HER2 Exon 20 insertion mutation • Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 • Strengthened executive team with the appointment of Fang Ni, Pharm.D., as Chief Business Officer • Cash, cash equivalents, and in
-
Black Diamond Therapeutics to Present at Upcoming Investor Conferences - Aug 05, 2020
8/5/2020
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences
-
Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer
8/4/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni, Pharm.D., as Chief Business Officer. “Fang’s proven track record in business development and corporate strategy, including his work as Black Diamond’s interim Chief Business Officer, gives us confidence that he has
-
Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation
7/28/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric human epidermal growth factor receptor 2 (HER2) mutation or an epidermal g
-
Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
6/16/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the BMO 2020 Prescriptions for Success Healthcare Conference.
-
Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference
5/27/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Jefferies Virtual Healthcare Conference. The presentation will take place on Wednesday, June 3, 2020, at 1:30 PM
-
Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020
5/13/2020
Black Diamond Therapeutics, Inc. announced that the design of MasterKey-01, the Company’s first-in-human Phase 1/2 clinical trial for its lead product candidate BDTX-189, will be presented as a poster presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program, taking place from May 29-31, 2020.
-
Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update
5/12/2020
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, reported financial results for the first quarter ended March 31, 2020, and provided a corporate update.
-
Black Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020
5/6/2020
Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Bank of America Global Research Health Care Conference 2020.
-
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
3/24/2020
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019, while providing a corporate update.
-
Black Diamond Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
2/24/2020
CAMBRIDGE, Mass. and NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s business at the Cowen and Company 40 th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on
-
Black Diamond Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
2/3/2020
Black Diamond Therapeutics, Inc. announced the closing of its initial public offering of 12,174,263 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.
-
Versant Ventures Announces Successful IPO by Black Diamond Therapeutics
1/30/2020
First company launched by Versant’s Ridgeline Discovery Engine
-
Black Diamond Therapeutics Announces Pricing of Initial Public Offering at $19.00 per share
1/30/2020
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share.
-
Black Diamond Therapeutics Closes $85 Million Series C Financing
12/5/2019
Company also announces CRISPR Therapeutics CEO Samarth Kulkarni, Ph.D., Joins its Board of Directors